TD Cowen Insights
TD Securities, TD Cowen
On each episode of "TD Cowen Insights", members of our firm host leading thinkers to share insights and ideas shaping the world economy. Join us, as we converse with the top minds who are influencing our global sectors.
Disclosures: https://go.td.com/PodcastDisclosure
Disclosures: https://go.td.com/PodcastDisclosure
Episodes
Mentioned books
Oct 10, 2025 • 19min
Tools/Dx Team Talks Trends & Themes From Our 14th Annual MedTools Conference
Recorded on 10/10/25TD Cowen's The Future Is Now podcast series, hosted by health care analysts Dan Brennan and Brendan Smith, discusses emerging themes and critical investment topics across the life science tools and diagnostics sector. The series focuses on key takeaways from the team's proprietary conferences, unpacking the macroeconomic and geopolitical environment of the sector and the impact on emerging R&D spend trends across the health care industry.In this episode, Dan and Brendan highlight the biggest takeaways from TD Cowen's 14th Annual MedTools Conference. The team hosted 10 different key opinion leaders across four panel sessions, with more than 100 investors on site to discuss four main topics: 1) The AI Era of Tools/Dx; 2) The Future of Bioprocessing; 3) Pharma R&D Spending Trends; and 4) Multi-Cancer Early Detection (MCED). The discussion includes insights on how to contextualize key growth drivers in the sector today, expectations for 2026, and how innovation across the space is disrupting long-established tools spending paradigms.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Oct 7, 2025 • 17min
State of Housing & Policy Agenda for October
Recorded on 10/03/25TD Cowen financial policy analyst Jaret Seiberg hosts TD Cowen's Two Cents Podcast, which includes a discussion of the state of housing with Max Rakhlenko, TD Cowen equity analyst and author of TD Cowen's monthly Housing Blueprint. We also get a market update and earnings preview from Scott Smith, the TD Cowen specialty salesperson for financials.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Oct 3, 2025 • 39min
Shutdown Showdown, Quantico Conclave, U.S. Foreign Military Sales & Some Program News
Recorded on 10/03/25 In this episode, Roman Schweizer, TD Cowen’s WRG geopolitics & defense analyst, and an All-Star reporter lineup discuss the outlook for the USG shutdown impasse, the Secretary of War's big meeting in Quantico, the strong final Foreign Military Sales tally for FY25, and some program updates, including F-35 and Golden Dome.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Sep 30, 2025 • 42min
Unlocking AI KPIs With Insilico CEO Alex Zhavoronkov
Recorded on 06/24/25TD Cowen's Machine Medicine: AI & Health Care podcast series takes on the cross-sector revolution in artificial intelligence and breaks it down one piece at a time. We highlight some of the biggest misconceptions about how AI is and can be used in different health care settings and aim to contextualize the latest and most impactful developments in a field defined by rapid innovation. In this episode, TD Cowen's health care analyst Brendan Smith hosts Alex Zhavoronkov, chief executive officer and founder of Insilico Medicine, to explore how Insilico is helping define some of the most important efficiency benchmarks and key performance indicators for AI in drug development. We discuss the difficulties investors face when assessing the relative productivity and competitive profile of different AI platforms and how important it is that AI players demonstrate and disclose quantifiable improvements that actually bend the curve on R&D efficiency.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Sep 25, 2025 • 34min
Leading Biotechs To Success
Recorded on 09/18/25.TD Cowen analyst Yaron Werber speaks with Ron Renaud, a Wall Street biotech veteran who turned into a seasoned biotech CEO and chairman of boards, as he outlines his decision to helm Kailera Therapeutics as President and CEO. Ron lays out Kailera's vision in obesity, a field that underpins one of the key global healthcare challenges. Backed by a $400M Series A and a strategic partnership with Jiangsu Hengrui, a large global pharma based in China with deep peptide chemistry expertise, the company is advancing both an injectable dual GLP1/GIP1 agonist and an oral GLP1 program to create a comprehensive, leading, late-stage, metabolic portfolio. Ron emphasizes how the partnership with Hengrui accelerates data flow and strategic decision-making. He stresses that guiding Kailera's growth requires the same principles he applies broadly in biotech: transparency, trust, surrounding yourself with great people, and stimulating the best in innovation and cooperation from the team.Ron also shares lessons from his impressive career spanning equity research, multiple biotech CEO roles, and three successful acquisitions by pharma (Idenix, Translate Bio, Cerevel) for a total $16B in value. He emphasizes that companies “get bought, not sold” — meaning value comes from building strong, enduring organizations with the right people and differentiated foundations.On leadership, Ron highlights the importance of transparency with boards and employees, especially during turbulent times of strategic refocusing/change, pipeline reprioritization, and recognizing the importance of every employee within a company. He stresses that good decision-making often comes from admitting what you don’t know and being unafraid to ask. For aspiring CEOs, he recommends surrounding yourself with trusted mentors and collaborators, focusing on culture as much as science, and learning to navigate nonlinear processes.If he wasn’t a biotech CEO, Ron would opt to be a teacher. Lastly, on a fun note, when asked to choose between jumping out of a plane or scuba diving to the bottom of the ocean, Ron, an avid fisherman, says that he would pick scuba diving because of his deep love of the ocean, as he can always figure out a way back to the surface.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Sep 25, 2025 • 40min
Powering the Future - How a Global Energy Leader Creates Value with a Diverse Asset Portfolio
Recorded on 09/23/25.Northland Power is a large-scale developer and operator of renewable, battery storage, and gas-fired power, with 3.5 gigawatts of operating capacity and an additional 2.2 gigawatts under construction. President and CEO Christine Healy provides a detailed overview of the company's diverse platform and compelling growth prospects across technologies and regions.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Sep 17, 2025 • 36min
Decoding Sephora with Beauty Advisory, View From 32
Recorded on 08/01/25How to Succeed in Sephora & Drive Longevity. We host Cassie Cowman, Co-Founder of View from 32, who explains why Sephora launches demand 9-18 months of planning, aligned KPIs, and flawless execution. We discuss Rare Beauty’s blush and Rhode’s lip as lessons in category ownership and highlight haircare’s styling wave. We also unpack how biotech + AI are key drivers amid rising market volatility and Ulta vs. Sephora dynamics.What's Next in Beauty and Wellness and What Will Work For the Long Term. In this episode, Cassie explains that longevity in beauty comes from owning categories and building replenishable hero SKUs, not chasing viral spikes, and highlights how Rare Beauty’s dominance in blush and Rhode’s lip play serve as case studies in the trade-offs between loyalty and virality. The discussion unpacks haircare’s next wave in styling, biotech and AI-driven skincare innovation, and the rise of “expert-led” brands driving category engagement. Cassie also contrasts Sephora’s disciplined brand-building with Ulta’s broader assortment, arguing that Ulta must sharpen curation, education, and services to compete in a market where consumer demand is more volatile than ever.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Sep 11, 2025 • 32min
Getting to know Zip, a major BNPL/POS financing provider
Recorded on 09/05/25In this episode, TD Cowen's Consumer Finance analyst Moshe Orenbuch hosts Zip Co CEO Cynthia Scott to explore what Zip does and its value proposition to consumers and merchants. We believe this is very relevant to our coverage of consumer finance companies including Affirm, given the fast growing BNPL industry in the U.S., competitive landscape, as well as Klarna's recent IPO.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Sep 10, 2025 • 31min
Deploying Private Equity In Biotech
Recorded on 09/04/25TD Cowen analyst Yaron Werber speaks with Ricky Sun about Bain Capital's collaborative edge with both the Life Sciences and Private Equity teams, their broader Asia strategy with a focus on Japan and China, advice for biotech CEOs and boards, and opportunities and challenges in the current life sciences investing landscape. Ricky shares his learnings from Bain’s recent carve-out/taking private of Mitsubishi Tanabe Pharma (valued at roughly $3.3B), and notably how leveraging deep scientific and operational expertise across the Life Sciences and Japanese Private Equity teams was crucial for deal execution. In what is one of the key underpinnings of this deal, he shares optimism that the streamlining of drug approvals within the Japanese PMDA, especially for orphan indications, will allow faster time to market, reduce requirements to conduct Ph1 studies in Japanese patients by employing data from Western patients, and facilitate earlier feedback to sponsors, which will expedite approvals. He also cites his experience from >80 deals that suggests that quality of management, sound decision making, and discipline in capital deployment are the key factors for success in biotech.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Sep 8, 2025 • 11min
Tokenization of Equity Trading; Financial Policy Schedule For September
Recorded on 09/04/25 TD Cowen financial policy analyst Jaret Seiberg hosts TD Cowen's Two Cents Podcast, which includes a discussion of tokenized equity trading with Reid Noch, who follows U.S. market structure at TD Cowen. We also get a market update from Scott Smith, the TD Cowen specialty salesperson for financials.
https://go.td.com/PodcastDisclosure Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.


